Some people with scalp psoriasis may experience only mild, fine scaling ... Scalp psoriasis causes a buildup of skin cells ...

Discover a study that investigates spesolimab, a monoclonal antibody that has been approved as the first GPP-specific therapy ...

The American Academy of Dermatology/National Psoriasis Foundation (AAD/NPF) guidelines state that "topical medications are the most common agents used to treat patients with mild or moderate ...

Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...

Otezla may cause mild side effects other than the ones ... However, if you have plaque psoriasis on your scalp, scratching may lead to temporary hair loss. Treatments such as Otezla may reduce ...

Sotyktu comes as an oral tablet and is used in adults to treat plaque psoriasis. Keep reading to learn about the common, mild, and serious side effects Sotyktu can cause. To learn more about ...

Crucially, it extends the label for the PDE 4 inhibitor to include people with mild psoriasis ... to-treat areas like the scalp," she pointed out. "The location of plaques may make the area ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Once-daily ICP-488 significantly improved PASI scores in patients with plaque psoriasis compared with placebo at week 12. The safety profile of ICP-488 was similar to placebo. ORLANDO — A once ...

Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...

"Mild-to-moderate patients represent over 80% of all plaque psoriasis cases, and for these patients, current effective oral treatment options are limited. Our belief is that SFA-002 is uniquely ...